Actively Recruiting
A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH
Led by Peking University First Hospital · Updated on 2022-04-25
2000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are establishing a prospective group of patients with plasma cell disorders (PCDs) to better understand these conditions and their treatments. This study focuses on various PCDs including multiple myeloma, amyloidosis, and other related disorders. It aims to explore how minimal residual disease (MRD) status relates to patient prognosis and investigate the role of the tumor microenvironment (TME) in the disease's development and progression. Patients with confirmed PCDs who are hospitalized and willing to participate will be followed over time. Biological samples such as peripheral blood, bone marrow aspirate, and urine will be collected before and after treatment to support future research. The study does not involve any intervention and participants will be regularly assessed at baseline, then at 1, 3, 6, and 12 months after treatment, followed by yearly visits. During the study, clinical and laboratory data along with biological samples will be gathered to analyze disease features and treatment responses. Follow-up visits will monitor patient progress and outcomes for up to ten years. The main outcome is to maintain a comprehensive cohort and understand the relationship between MRD and prognosis in PCD patients, while also supporting further studies on tumor clone evolution and disease mechanisms.
CONDITIONS
Brief Title
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a confirmed diagnosis of plasma cell disorders (PCDs) hospitalized at Peking University First Hospital
- Patients diagnosed with any of the following: monoclonal gammopathy of uncertain significance, smoldering myeloma, multiple myeloma, plasma cell leukemia, amyloidosis, light chain deposition disease, heavy chain deposition disease, Castleman's disease, POEMS syndrome, cryoglobulinemia, monoclonal gammopathy of renal significance, or monoclonal gammopathy of neurological significance
- Willingness to sign the informed consent form (ICF) to participate
You will not qualify if you...
- Presence of significant life-threatening comorbidities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline
Participants with plasma cell disorders undergo baseline clinical and laboratory assessments and biological sample collection.
1 baseline visit (in-person)
Duration - Up to 10 years
Participants are followed up regularly to monitor clinical status and disease progression through clinical and laboratory data collection.
Follow-up visits at 1, 3, 6, 12 months, then yearly after treatment
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, China
Actively Recruiting
Research Team
B
Bo Tang, PhD
Y
Yujun Dong, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here